Contents
Last regulatory review: 24 September 2026.
Introduction
In January 2026, India's health ministry reported that the Central Drugs Standard Control Organization (CDSCO) processes around 4,000 to 4,500 bioavailability and bioequivalence (BA/BE) study applications annually [1]. That volume points to a substantial, active research base. For sponsors weighing India, the more useful question is not simply whether capacity exists, but which facilities within that ecosystem can generate evidence a particular programme requires and how to distinguish them before committing to a study. India supplies approximately 20% of global generics demand, and more than half of its pharmaceutical exports go to highly regulated markets, including the United States and Europe [2]. This scale does not directly reflect the size or growth of India's BA/BE services market, but it helps explain how the country has developed a solid ecosystem for generic-drug development and regulatory submissions.
India's BA/BE ecosystem at a glance
BA/BE study applications processed annually by CDSCO, according to the January 2026 health ministry report [1].
Share of global generics demand supplied by India [2].
Share of India's pharmaceutical exports going to highly regulated markets including the United States and Europe [2].
These figures illustrate ecosystem scale and pharmaceutical export orientation. They do not establish current site capacity, BA/BE market growth, protocol suitability, or the quality of any individual facility.
India's BA/BE Landscape Today
CDSCO's register, published in June 2025, lists clinical-only study units, stand-alone bioanalytical laboratories, and facilities combining clinical and bioanalytical activities [3]. These operating models raise different questions for sponsors. For example, a clinical unit working with an external laboratory requires coordination across sample transfer, data reconciliation, and oversight, whereas an integrated provider manages these activities within a single organisation.
The register is therefore a useful starting point for identifying potential facilities, but it is not a live measure of current capacity or study readiness. Appearing on the register confirms that the named facility was listed by CDSCO as of the June 2025 register; it does not establish current capacity, compliance status, or protocol suitability, and it does not indicate whether the proposed team, laboratory or clinical unit is available for a specific protocol.
Independent inspection and regulatory records can add an additional layer of evidence during qualification, but their relevance is specific to the facility, activity and time period assessed. Sponsors should consider what was inspected, when the inspection occurred, which systems and activities were covered, what observations were reported, and whether the evidence is relevant to the intended submission market.
Regulatory Changes Shaping BA/BE Studies in India
Alongside facility-level qualification, sponsors also need to account for changes in India's regulatory pathway for BA/BE studies. One significant operational change followed the January 2026 regulatory announcement. On 21 April 2026, CDSCO opened a dedicated online prior-intimation route under G.S.R. 50(E) for eligible export-only studies, replacing separate prior study permission with online submission and acknowledgement; ethics approval remains required [4]. (Regulatory status in this section reflects the source documents as of 24 September 2026.)
The route is limited to specified single-dose, two-period, two-sequence, two-treatment studies of eligible oral products in healthy adults, and only for products already approved in India or in one of six reference jurisdictions: the United States, the European Union, Japan, Australia, Canada or the United Kingdom [4]. Cytotoxic, hormonal, narcotic and psychotropic drugs are excluded, along with narrow-therapeutic-index drugs and drugs with highly variable pharmacokinetics [4]. The acknowledgement is normally valid for one year from its date of issue, with a further one-year extension possible in exceptional circumstances on written request, and no changes are accepted once it has been issued, so sponsors need a settled protocol before filing rather than treating the route as a placeholder [4]. Where a new drug or other substance must be imported for the study, a separate CT-16 application and prior approval remain necessary, so the prior-intimation route shortens one step in start-up, not the whole regulatory sequence [4]. Sponsors therefore need to confirm whether a proposed protocol qualifies rather than modifying a scientifically appropriate design simply to fit the administrative pathway. A single-dose, two-period crossover study of a conventional immediate-release tablet in healthy adults is a typical fit for the route. A replicate-design study, a study of a highly variable drug, a study of a narrow-therapeutic-index drug, or a study that requires patients rather than healthy volunteers would each fall outside the route on its own grounds and follow the standard permission process instead. A draft dated 3 September 2026 proposes removing the export-only restriction, which as of this writing remains a proposal rather than a final rule [5].
Which BA/BE studies may use India's prior-intimation pathway?
Decision 1
Is the study eligible for the G.S.R. 50(E) prior-intimation pathway?
Product already approved in India or one of the six reference jurisdictions:
If YES
Online prior intimation + acknowledgement
- Ethics approval still required
- Normally valid for 1 year
- Possible further 1-year extension in exceptional circumstances
- No changes accepted after acknowledgement
- CT-16 still required where import approval is needed
If NO
Standard permission process
- replicate-design study
- highly variable drug
- narrow-therapeutic-index drug
- patient study rather than healthy-volunteer study
- cytotoxic drug
- hormonal drug
- narcotic drug
- psychotropic drug
Sponsors should confirm whether the scientifically appropriate protocol qualifies for the pathway rather than redesigning a study simply to fit the administrative route.
International submission requirements sit alongside these domestic processes. ICH M13A, covering immediate-release solid oral dosage forms, took effect in the European Union on 25 January 2025, replacing applicable elements of previous bioequivalence guidance rather than superseding the wider framework in full [6],[8]. A further guideline in the same series, M13C, is intended to address highly variable drugs and narrow-therapeutic-index drugs specifically; as of ICH's own 2026 work plan, it is targeted for Step 1/2 in mid-2027 and Step 4 final adoption in late 2028, so those product categories are not yet covered by a finalized M13-series guideline [14]. FDA likewise continues to issue and update product-specific recommendations for generic drug development [7].
Indian regulatory authorization and suitability for an international submission therefore answer different questions. Sponsors still need to assess whether the proposed protocol, facility, laboratory, and study team can meet the requirements of the product, dosage form, and intended regulatory market.
Why India Merits Reassessment
The case for reassessing India does not depend on claiming that average site quality has risen across the country. What has changed is the context in which sponsors are making the decision.
India has a substantial volume of BA/BE activity, an export-oriented pharmaceutical sector serving highly regulated markets, an identifiable network of registered study centres and bioanalytical laboratories, and a regulatory pathway that changed in 2026 for a defined category of studies.
For qualifying protocols, the prior-intimation system removes one layer of pre-study regulatory processing. Whether that translates into shorter overall start-up timelines will depend on implementation, ethics approval, site readiness, and the study itself.
Taken together, these developments make India worth reassessing rather than simply viewing through historical assumptions about cost or outsourcing. They do not, however, change the fundamental qualification standard. The same principle would apply in any geography; country-level indicators can justify taking a closer look, but the decision to place a study should be based on the protocol, facility, laboratory and executing team.
Looking Beyond the Headline Cost
Cost competitiveness remains relevant, but only when quotations are compared against the same protocol and scope.
Screening, supervised clinical stays, method development and validation, sample analysis, monitoring, statistics, and reporting can all affect the true study cost. Sponsors should also identify how work outside the original assumptions, such as additional screening or analytical investigations, will be handled and priced.
The relevant question is therefore not simply which site submits the lowest price, but what it will cost to generate reliable, usable evidence within the required timeframe.
Importantly, even a well-conducted study can still legitimately fail to demonstrate bioequivalence. Site selection should reduce avoidable execution risk, not guarantee a scientific outcome.
From Market Opportunity to Site Selection
Country-level indicators can justify taking a closer look at India, but they cannot establish whether a particular facility is suitable for a particular programme. Sponsors therefore need to move from market-level indicators to study-specific evidence.
Four questions provide a practical starting point:
A. Can the facility deliver the study?
Sponsors should look beyond the size of a volunteer database or nominal bed capacity. A credible feasibility discussion should cover protocol-relevant recruitment, screening retention, clinical slots, laboratory schedules, and medical coverage; the availability of the proposed team provides a more useful picture of current capacity.
B. Has the team solved similar problems before?
A large lifetime study count is less informative than experience with comparable dosage forms, study designs, analytical requirements, and therapeutic risks. It is important to distinguish organisational experience from the experience of the people assigned to the study. A company may have completed relevant work at another facility or with a team that is no longer available.
The question is not simply, "Has this organisation done this before?" It is, "Has the team that will execute this study dealt with sufficiently similar scientific and operational problems?"
C. Can the data be reconstructed?
Relevant experience should be supported by records that allow the study to be reconstructed after completion [9].
Sponsors should be able to trace a reported result through source documentation, dosing, sample collection and handling, bioanalysis, and associated records. FDA's compliance program for BA/BE inspections addresses the clinical phase specifically and does not extend to analytical or bioanalytical laboratory inspection [10]. Where analysis is outsourced, qualification should therefore also cover the executing laboratory directly, including its adherence to bioanalytical method validation and sample-analysis controls [11], together with the sponsor's own documented oversight of that delegated activity [13].
D. What does the regulatory record show?
An inspection history can be informative, but "this site has been inspected" is not enough [12].
Sponsors should therefore obtain the relevant records rather than assume that one inspection covers every facility, activity, or team within an organisation. Corrective actions also deserve attention. The useful question is not only whether an observation was addressed, but whether the organisation subsequently confirmed that the corrective action worked and whether similar issues recurred.
Turning the Four Questions Into a Diligence Checklist
A practical BA/BE site diligence checklist
| Question | Evidence to request | Warning sign |
|---|---|---|
| Can the facility deliver the study? | A protocol-specific recruitment plan, screening and retention rates, and clinical slot and lab scheduling for the proposed window | Confidence about bed capacity or database size with no study-specific numbers behind it |
| Has the team solved similar problems before? | CVs and study history of the specific team assigned, not just the organisation's overall track record | A lifetime study count is cited, but no one can name the team that will run this protocol |
| Can the data be reconstructed? | Source documentation and chain-of-custody records from dosing through the reported result, plus the outsourced laboratory's own controls if analysis sits elsewhere | An incomplete or unclear audit trail between clinical conduct and the final result |
| What does the regulatory record show? | Available inspection correspondence, classifications, observations, responses, and relevant CAPA evidence | One inspection is presented as if it covers every facility, activity, or time period at the organisation |
Question
Can the facility deliver the study?
Evidence to request
A protocol-specific recruitment plan, screening and retention rates, and clinical slot and lab scheduling for the proposed window
Warning sign
Confidence about bed capacity or database size with no study-specific numbers behind it
Question
Has the team solved similar problems before?
Evidence to request
CVs and study history of the specific team assigned, not just the organisation's overall track record
Warning sign
A lifetime study count is cited, but no one can name the team that will run this protocol
Question
Can the data be reconstructed?
Evidence to request
Source documentation and chain-of-custody records from dosing through the reported result, plus the outsourced laboratory's own controls if analysis sits elsewhere
Warning sign
An incomplete or unclear audit trail between clinical conduct and the final result
Question
What does the regulatory record show?
Evidence to request
Available inspection correspondence, classifications, observations, responses, and relevant CAPA evidence
Warning sign
One inspection is presented as if it covers every facility, activity, or time period at the organisation
How Kitsa Supports BA/BE Site Discovery
A market worth reassessing is not the same as a site worth selecting. What sponsors need next is a way to move from that country-level picture to a specific, qualified facility.
Kitsa's Site Network supports exactly this discovery stage: it helps sponsors identify research organisations and review reported capabilities in one place, turning a broad country-level search into a focused shortlist before detailed feasibility and qualification begin. It is a starting point for investigation, not a substitute for direct verification and study-specific qualification.
India's registered BA/BE ecosystem includes a mix of dedicated CROs, integrated clinical and bioanalytical facilities, specialist laboratories and pharmaceutical-company research units. CDSCO's register illustrates that diversity, with organisations operating across major research clusters including Mumbai, Hyderabad, Ahmedabad, Pune, Bengaluru and other centres [3].
Several organisations across India are also part of the Kitsa Site Network, including:
- GloGen Clinical Research, Hyderabad, Telangana
- CliniSpec Research, Hyderabad, Telangana
- Hemex Research, Mumbai, Maharashtra
- IndiGlobal Labs Pvt. Ltd., Hyderabad, Telangana
- Notrox Research, Bangalore, Karnataka
- Vayam Research Solutions Limited, Gandhinagar, Gujarat
- Cliantha Research Ltd., Vadodara, Gujarat
These organisations represent different operating models, geographies and stages of development within India's BA/BE ecosystem; several are registered as combined clinical and bioanalytical facilities, while others bring different combinations of clinical, laboratory, and development capabilities. That diversity is why the objective should not be to identify the "best" site nationally, but to determine which organisation is best aligned with a given programme, using the same due-diligence questions and checklist outlined above. Kitsa can make that first stage of the process more efficient by bringing potential organisations into view; the decision to proceed should still depend on direct feasibility, documentation, and study-specific qualifications.
Key Takeaways
- India's BA/BE ecosystem is substantial, but scale alone is not a qualification criterion. CDSCO processes around 4,000 to 4,500 BA/BE study applications annually, and the country has a broad network of registered clinical and bioanalytical facilities.
- The 2026 prior-intimation route is narrower than it first appears. It covers a specific study design, requires the product to already be approved in India or one of six reference jurisdictions, excludes several drug categories, normally carries a one-year acknowledgement validity (with a possible further one-year extension in exceptional circumstances) and no post-acknowledgement changes, and still leaves a separate CT-16 import approval in place.
- Site-level diligence should follow four questions: can the facility deliver the study, has the assigned team handled similar work before, can the resulting data be reconstructed, and what does the regulatory record actually show.
- Cost should be evaluated against a matched protocol and scope, covering screening, clinical stays, analytical work, monitoring, statistics, and reporting, since a lower headline quotation is only meaningful when the underlying assumptions line up.
- A listing in a discovery tool such as Kitsa's Site Network is not the same as current CDSCO registration; both should be verified directly before a facility is qualified for a specific programme.
FAQ
What is the difference between bioavailability and bioequivalence?
Bioavailability describes the rate and extent to which an active drug ingredient becomes available in the body. Bioequivalence compares a test product with a reference product to determine whether their exposure is sufficiently similar under defined study conditions [8].
Why is India being reconsidered for BA/BE studies?
India combines substantial BA/BE study activity, an established generic-drug industry, a large network of registered clinical and bioanalytical facilities, and recent regulatory changes affecting eligible studies. These factors make the country relevant for consideration, but they do not remove the need for study-specific site qualification.
Are all BA/BE studies conducted in healthy volunteers?
No. Healthy volunteers are commonly used in many bioequivalence studies because they can reduce variability unrelated to the formulation being compared [8]. Patients may be required where safety, ethical or product-specific considerations make healthy-volunteer participation inappropriate.
Does CDSCO registration mean a site is suitable for international submission?
No. Appearance on the CDSCO register confirms that the named facility was listed as of the register's date; it does not establish current capacity, compliance status, protocol fit, or suitability for a particular submission market. Sponsors still need to assess the proposed facility, laboratory, team and applicable international guidance directly.
What should sponsors evaluate when shortlisting a BA/BE facility?
A useful assessment should cover protocol-specific recruitment and capacity, relevant experience of the assigned team, analytical capability, data traceability, inspection history, corrective actions and the facility's ability to meet the requirements of the intended regulatory market.
Is the lowest cost BA/BE site necessarily the best option?
No. A lower quotation may offer good value, but only if the scope, assumptions and delivery plan are comparable. Sponsors should examine what is included, what may trigger additional work or charges, and whether the facility can generate reliable evidence within the required timeframe.
How can Kitsa support BA/BE site discovery in India?
Kitsa can support the early discovery stage by helping sponsors identify research organisations and review reported capabilities across the market. It should be used to inform shortlisting rather than replace direct feasibility, documentation review and study-specific qualification.
References
- [1]Ministry of Health and Family Welfare / Press Information Bureau. "Union Health Ministry Notifies Key Amendments to NDCT Rules, 2019." 28 January 2026. https://www.pib.gov.in/PressReleasePage.aspx?PRID=2219422&lang=1®=3
- [2]Department of Pharmaceuticals / Press Information Bureau. "Economic Survey 2025-26 Highlights India's Shift Toward High-Value Pharma and Innovation." 30 January 2026. https://pib.gov.in/PressReleasePage.aspx?PRID=2221080
- [3]CDSCO. "List of registered BA/BE study centres and bioanalytical laboratories." June 2025. (accessed 24 September 2026) https://cdsco.gov.in/opencms/resources/UploadCDSCOWeb/2018/UploadAlertsFiles/LIST%20OF%20REGISTRED%20BABE%20site%20ason%2026.06.2025.pdf
- [4]CDSCO. Implementation circular, 20 April 2026, for the prior-intimation system under G.S.R. 50(E), operational from 21 April 2026, with accompanying FAQs. (accessed 24 September 2026) Circular: https://cdsco.gov.in/opencms/resources/UploadCDSCOWeb/2018/UploadCircularFile/Circular_20042026.pdf FAQs: https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/FAQ-for-Prior-Intemation-BA-BE-studies-GSR-50E-21.01.2026-2.pdf
- [5]Ministry of Health and Family Welfare. G.S.R. 790(E), dated 3 September 2026. Draft amendment proposing extension of prior intimation beyond export-only studies; still a draft, not a final rule, as of the access date below. (accessed 24 September 2026) https://cdsco.gov.in/opencms/resources/UploadCDSCOWeb/2018/UploadGazette_NotificationsFiles/2026.09.03%20G.S.R.%20790%28E%29_Draft%20Notification%20for%20extension%20of%20prior%20intimation%20system%20for%20certain%20BA%20and%20BE%20studies%20for%20approval%20of%20New%20Drugs%20in%20India.pdf
- [6]EMA. "ICH Guideline M13A on bioequivalence for immediate-release solid oral dosage forms." Effective 25 January 2025. (accessed 24 September 2026) https://www.ema.europa.eu/en/ich-guideline-m13a-bioequivalence-immediate-release-solid-oral-dosage-forms-scientific-guideline
- [7]FDA. "Product-Specific Guidances for Generic Drug Development." (accessed 24 September 2026) https://www.fda.gov/drugs/guidances-drugs/product-specific-guidances-generic-drug-development
- [8]ICH / FDA. "M13A: Bioequivalence for Immediate-Release Solid Oral Dosage Forms." Final guidance, October 2024; sections 1 and 2.1.1. (accessed 24 September 2026) https://www.fda.gov/media/165049/download
- [9]WHO. "Guidance for organizations performing in vivo bioequivalence studies." Technical Report Series 996, Annex 9, 2016; definitions in section 2, computer-system record retention in section 4 (paras 4.21-4.23), and analytical raw-data traceability in section 23 (para 23.6). (accessed 24 September 2026) https://www.who.int/docs/default-source/medicines/norms-and-standards/guidelines/regulatory-standards/trs966-annex9-invivo-bioequivalence-studies.pdf
- [10]FDA. Compliance Program 7348.003: "In Vivo Bioavailability/Bioequivalence Studies (Clinical)." Issued 1 May 2018. Scope is limited to the clinical phase; the program states its analytical inspection section is not applicable. (accessed 24 September 2026) https://www.fda.gov/media/112538/download
- [11]ICH / FDA. M10: "Bioanalytical Method Validation and Study Sample Analysis." Final guidance, November 2022. (accessed 24 September 2026) https://www.fda.gov/media/162903/download
- [12]FDA. "Inspection classifications." (accessed 24 September 2026) https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-basics/inspection-classifications
- [13]ICH. "Good Clinical Practice E6(R3)." Step 4 Final Guideline with error corrections, 2025. (accessed 24 September 2026) https://database.ich.org/sites/default/files/ICH_E6%28R3%29_Step4_FinalGuideline_2025_0106_ErrorCorrections_2025_1024.pdf
- [14]ICH. M13 EWG Work Plan, 2026, showing M13C targeted for Step 1/2 endorsement in June-July 2027 and Step 4 final adoption in October-November 2028. (accessed 24 September 2026) https://database.ich.org/sites/default/files/ICH52_M13_EWG_WorkPlan_2026_0318_0.pdf